The involvement of specific anti myelin basic protein antibody-forming cells in multiple sclerosis immunopathology

doi:10.1016/0165-5728(94)90191-0

Journal of Neuroimmunology

Volume 49, Issues 1–2, January 1994, Pages 153-159

https://doi.org/10.1016/0165-5728(94)90191-0 Get rights and content

Abstract

Irrespective of the large body of literature on the putative role of antibodies in the development of multiple sclerosis (MS), the detection of specific antibody-forming B cells (AFCs) in the central nervous system (CNS) tissues has not been described. In this study we show that autoantigen-specific AFCs can be found in CNS tissue sections of MS patients. Applying a newly developed myelin basic protein (MBP)-enzyme conjugate technique, we have detected MBP-specific AFCs in autopsy periventricular white matter and cerebellum tissue sections of MS patients. We demonstrated the presence of MBP-specific AFCs in CNS tissue sections in five out of 12 MS patients. No MBP-specific AFCs were detected in CNS tissue sections of 11 patients with other neurological diseases, such as Parkinson's and Alzheimer's disease, or in brain tissue sections of eight deceased persons without neurological diseases. In MS patients, anti-MBP AFCs were present in brain tissue sections both with and without plaques. The proportion of MBP-specific AFCs in some of the MS patient brain tissues reached over 50% of all AFCs. The high relative frequency of the anti-MBP AFCs and their localization in periventricular white matter and cerebellum of MS patients only, suggests that anti-MBP AFCs represent a cell population, which could play an important role in MS immunopathology.

References (37)

M. Geffard et al.
Seric immune complexes in multiple sclerosis do not contain MBP epitopes
Brain Res. Bull.
(1993)
A. Henneberg et al.
Antibodies to brain tissue in sera of patients with chronic progressive multiple sclerosis
J. Neuroimmunol.
(1991)
W.J. Karpus et al.
Protection against experimental autoimmune encephalomyelitis requires both CD4⁺ T suppressor cells and myelin basic protein primed B cells
J. Neuroimmunol.
(1991)
J.A. Killen et al.
Regulation of experimental allergic encephalomyelitis. IV. Further characterization of post recovery suppressor cells
J. Neuroimmunol.
(1982)
H. Link et al.
Persistent anti-myelin basic protein IgG antibody response in multiple sclerosis cerebrospinal fluid
J. Neuroimmunol.
(1990)
T.C. Ruijs et al.
Serum cytotoxicity to human and rat oligodendrocytes in culture
Brain Res.
(1990)
J. Satoh et al.
Cytolysis of oligodendrocytes is mediated by killer (K) cells but not by natural killer (NK) cells
J. Neuroimmunol.
(1991)
K.G. Warren et al.
A myelin basic protein antibody cascade in purified IgG from cerebrospinal fluid of multiple sclerosis patients
J. Neurol. Sci.
(1990)
K.G. Warren et al.
Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
J. Neuroimmunol.
(1992)
K.G. Warren et al.
Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis
J. Neuroimmunol.
(1993)

J.P. Zanetta et al.

Antibodies to cerebellar soluble lectin CSL in multiple sclerosis

Lancet

(1990)

S. Baig et al.

Multiple sclerosis: cells secreting antibodies against myelin-associated glycoprotein are present in cerebrospinal fluid

Scand. J. Immunol.

(1991)

E. Cash et al.

Cells of cerebrospinal fluid of multiple sclerosis patients secrete antibodies to myelin basic protein in vitro

Scand. J. Immunol.

(1992)

C.H.J. Chou et al.

Failure to detect antibodies to myelin basic protein or peptide fragments of myelin basic protein in CSF of patients with MS

Neurology

(1983)

E. Claassen et al.

Double-enzyme conjugates, producing an intermediate color, for simultaneous and direct detection of three different intracellular immunoglobulin determinants with only two enzymes

J. Histochem. Cytochem.

(1986)

E. Claassen et al.

New immunoenzyme-cytochemical stainings for the in situ detection of epitope specificity and isotype of antibody-forming B cells in experimental and natural (auto)immune responses in animals and man

J. Immunol. Methods

(1992)

P.K. Coyle et al.

Multiple sclerosis immune complexes: An analysis of component antigens and antibodies

Ann. Neurol.

(1984)

M.K. Dasgupta et al.

Myelin basic protein: A component of circulating immune complexes in multiple sclerosis

Can. J. Neurol. Sci.

(1983)

Cited by (42)

Pathology of multiple sclerosis and related inflammatory demyelinating diseases
2014, Handbook of Clinical Neurology
Citation Excerpt :
Their biologic relevance is so far undetermined. A single, so far unconfirmed, study used biotinylated myelin basic protein (MBP) as a tool to identify MBP antibody-producing B cells in MS lesions and the authors described that up to 50% of local plasma cells in the lesions produce MBP-reactive autoantibodies (Gerritse et al., 1994). This seems to be an unrealistically high percentage, considering both the multitude of potential autoantigens and the difficulties in unequivocally identifying autoantibodies in the cerebrospinal fluid of MS patients.
This article provides a comprehensive overview of the pathology of multiple sclerosis (MS), including recent insights into its molecular neuropathology and immunology. It shows that all clinical manifestations of relapsing and progressive MS display the same basic features of pathology, such as chronic inflammation, demyelination in the white and gray matter, and diffuse neurodegeneration within the entire central nervous system. However, the individual components of the pathological spectrum vary quantitatively between early relapsing and late progressive MS. Widespread confluent and plaque-like demyelination with oligodendrocyte destruction is the unique pathological hallmark of the disease, but axonal injury and neurodegeneration are additionally present and in part extensive. Remyelination of existing lesions may occur in MS brains; it is extensive in a subset of patients, while it fails in others. Active tissue injury in MS is always associated with inflammation, consistent with T-cell and macrophage infiltration and microglia activation. Recent data suggest that oxidative injury and subsequent mitochondrial damage play a major pathogenetic role in neurodegeneration. Finally we discuss similarities and differences of the pathology between classical MS and other inflammatory demyelinating diseases, such as neuromyelitis optica, concentric sclerosis, or acute disseminated encephalomyelitis.
Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients
2013, Journal of Neuroimmunology
Citation Excerpt :
The most important evidence for the involvement of B cells comes from the finding of oligoclonal immunoglobulin G (IgG) bands (OCBs) in the cerebrospinal fluid (CSF) of more than 90% of MS patients (Kabat et al., 1948; Cole et al., 1998). Further, the presence of B cells, plasma cells, complement, myelin-specific antibodies and B cell cytokines was reported in chronic MS lesions (Esiri, 1977; Gerritse et al., 1994; Genain et al., 1999; Archelos et al., 2000; Cross et al., 2001; Krumbholz et al., 2005; Ziemssen and Ziemssen, 2005). The most frequent (approximately 58%) lesion type in MS patients is the pattern II demyelinating lesion, characterized by immunoglobulin (Ig) deposits and involvement of the complement system (Lucchinetti et al., 2000).
We studied Ig heavy chain (VDJ) sequences and antigen reactivity of 412 immortalized B cell lines from the peripheral blood of 10 multiple sclerosis (MS) patients, 4 clinically isolated syndrome (CIS) patients and 6 healthy controls (HCs). 78/238 (32.8%) MS and CIS B cell lines were part of 9 clonally expanded B cell populations, of which 5 were present in multiple patients. Increased VH1 gene family usage was evidenced for MS B cells, with 29.2% expressing VH1–69. Affinity maturation in MS and CIS was indicated by increased Ig VDJ mutations. Autoantibody producing B cells reactive to intracellular antigens were significantly higher in MS (25%) and CIS (28%) patients than in HCs (5%), including 3/9 expanded B cell clones. Specificity for phosphatidylcholine was observed for 1/9 B cell clones. These findings indicate clonally expanded autoreactive B cells with affinity maturation in the peripheral blood in MS and CIS.
A putative bioactive conformation for the altered peptide ligand of myelin basic protein and inhibitor of experimental autoimmune encephalomyelitis [Arg<sup>91</sup>, Ala<sup>96</sup>] MBP<inf>87-99</inf>
2006, Journal of Molecular Graphics and Modelling
[Arg⁹¹, Ala⁹⁶] MBP_87–99 is an altered peptide ligand (APL) of myelin basic protein (MBP), shown to actively inhibit experimental autoimmune encephalomyelitis (EAE), which is studied as a model of multiple sclerosis (MS). The APL has been rationally designed by substituting two of the critical residues for recognition by the T-cell receptor. A conformational analysis of the APL has been sought using a combination of 2D NOESY nuclear magnetic resonance (NMR) experiments and detailed molecular dynamics (MD) calculations, in order to comprehend the stereoelectronic requirements for antagonistic activity, and to propose a putative bioactive conformation based on spatial proximities of the native peptide in the crystal structure. The proposed structure presents backbone similarity with the native peptide especially at the N-terminus, which is important for major histocompatibility complex (MHC) binding. Primary (Val⁸⁷, Phe⁹⁰) and secondary (Asn⁹², Ile⁹³, Thr⁹⁵) MHC anchors occupy the same region in space, whereas T-cell receptor (TCR) contacts (His⁸⁸, Phe⁸⁹) have different orientation between the two structures. A possible explanation, thus, of the antagonistic activity of the APL is that it binds to MHC, preventing the binding of myelin epitopes, but it fails to activate the TCR and hence to trigger the immunologic response. NMR experiments coupled with theoretical calculations are found to be in agreement with X-ray crystallography data and open an avenue for the design and synthesis of novel peptide restricted analogues as well as peptide mimetics that rises as an ultimate goal.
High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse
2006, Journal of Neuroimmunology
The aim of our study was to determine whether high doses of intravenous methylprednisolone have significant impact on immune parameters during the multiple sclerosis (MS) exacerbations. Peripheral blood of 32 MS patients was evaluated, using two-color flow cytometry before glucocorticosteroids and after 7 days from starting therapy. Significant increase of B cells, decrease of NK cells and monocytes producing IL-8 were observed after treatment. IL-8 is one of the cytokines responsible for blood–brain-barrier disruption and migration of immune cells to the central nervous system; in this aspect, explaining glucocorticosteroid effects during MS exacerbations.
B and T cells in the brains of autoimmune mice
2004, Journal of Neuroimmunology
Systemic lupus erythematosus (SLE) is an autoimmune disorder that can involve the central nervous system (CNS). Recently, we reported the presence of autoantibodies bound to the brain tissue of murine models of lupus; MRL/lpr and BXSB. We postulated that the source of these autoantibodies was in part due to in situ production, caused by the entry of B and T cells. Frozen brain sections of MRL/lpr and BXSB at 1 and 4 months of age were stained for CD3 (T cells) and CD19 (B cells) markers using an immunofluorescent antibody binding assay. Confocal fluorescence microscopy showed both CD3⁺ and CD19⁺ cells at 4 months of age only in MRL/lpr mice. There were no lymphocytes seen in the other autoimmune model, BXSB. Results suggest a difference in the mechanisms by which autoantibodies access the brain in these two autoimmune models of lupus.
Cellular Damage and Repair in Multiple Sclerosis
2004, Myelin Biology and Disorders
Multiple sclerosis is a chronic inflammatory demyelinating disease. The pathology of multiple sclerosis is defined by the presence of demyelinated plaques. Demyelination is associated with a variable extent of axonal and neuronal injury, which may lead to secondary degeneration of respective tracts or projection areas. The mechanisms of demyelination and tissue destruction are complex and heterogeneous among patients. This heterogeneity is most likely controlled by genes of the patients, influencing qualitatively and quantitatively the type of the immune response that is responsible for tissue injury. In addition, genetic factors appear to control the susceptibility of the target tissue for immune-mediated injury, and to determine the capacity of the tissue for remyelination and repair. MS is thus not unlike other chronic immunological diseases in which an exogenous trigger initiates a cascade of events, and which in their quantity and quality are determined by the genetic background of the patient. The complexity of such a disease, however, explains why curative therapies are so difficult to establish.

View all citing articles on Scopus

View full text

The involvement of specific anti myelin basic protein antibody-forming cells in multiple sclerosis immunopathology

Abstract

Brain Res. Bull.

J. Neuroimmunol.

J. Neuroimmunol.

J. Neuroimmunol.

J. Neuroimmunol.

Brain Res.

J. Neuroimmunol.

J. Neurol. Sci.

J. Neuroimmunol.

J. Neuroimmunol.

Lancet

Multiple sclerosis: cells secreting antibodies against myelin-associated glycoprotein are present in cerebrospinal fluid

Scand. J. Immunol.

Cells of cerebrospinal fluid of multiple sclerosis patients secrete antibodies to myelin basic protein in vitro

Scand. J. Immunol.

Failure to detect antibodies to myelin basic protein or peptide fragments of myelin basic protein in CSF of patients with MS

Neurology

Double-enzyme conjugates, producing an intermediate color, for simultaneous and direct detection of three different intracellular immunoglobulin determinants with only two enzymes

J. Histochem. Cytochem.

New immunoenzyme-cytochemical stainings for the in situ detection of epitope specificity and isotype of antibody-forming B cells in experimental and natural (auto)immune responses in animals and man

J. Immunol. Methods

Multiple sclerosis immune complexes: An analysis of component antigens and antibodies

Ann. Neurol.

Myelin basic protein: A component of circulating immune complexes in multiple sclerosis

Can. J. Neurol. Sci.